Fluticasone has extremely potent vasoconstrictive and anti-inflammatory activity.
Because fluticasone and salmeterol act locally in the lung, plasma levels do not predict therapeutic effect.įluticasone: The mechanism of action for all topical corticosteroids is believed to be a combination of three important properties: Anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions. Excipient information presented when available (limited, particularly for generics) consult specific product labeling.Ĥ5/21: Fluticasone propionate 45 mcg and salmeterol 21 mcg per inhalation (8 g, 12 g) ġ15/21: Fluticasone propionate 115 mcg and salmeterol 21 mcg per inhalation (8 g, 12 g) Ģ30/21: Fluticasone propionate 230 mcg and salmeterol 21 mcg per inhalation (8 g, 12 g) ġ00/50: Fluticasone propionate 100 mcg and salmeterol 50 mcg (14s, 60s) Ģ50/50: Fluticasone propionate 250 mcg and salmeterol 50 mcg (14s, 60s) ĥ00/50: Fluticasone propionate 500 mcg and salmeterol 50 mcg (14s, 60s) ĥ5/14: Fluticasone propionate 55 mcg and salmeterol 14 mcg (0.45 g) ġ13/14: Fluticasone propionate 113 mcg and salmeterol 14 mcg (0.45 g) Ģ32/14: Fluticasone propionate 232 mcg and salmeterol 14 mcg (0.45 g) ġ00/50: Fluticasone propionate 100 mcg and salmeterol 50 mcg (60s)Ģ50/50: Fluticasone propionate 250 mcg and salmeterol 50 mcg (60s)ĥ00/50: Fluticasone propionate 500 mcg and salmeterol 50 mcg (60s)ĥ5/14: Fluticasone propionate 55 mcg and salmeterol 14 mcg (0.45 g)ġ00/50: Fluticasone propionate 100 mcg and salmetrol 50 mcg (60s)ġ13/14: Fluticasone propionate 113 mcg and salmeterol 14 mcg (0.45 g)Ģ32/14: Fluticasone propionate 232 mcg and salmeterol 14 mcg (0.45 g)Ģ50/50: Fluticasone propionate 250 mcg and salmetrol 50 mcg (60s)ĥ00/50: Fluticasone propionate 500 mcg and salmetrol 50 mcg (60s)Ĭombination of fluticasone (corticosteroid) and salmeterol (long-acting beta 2-agonist) designed to improve pulmonary function and control over what is produced by either agent when used alone.